ASP Isotopes Inc. (ASPI) is a Nasdaq-listed, development-stage advanced-materials company that enriches isotopes used in nuclear fuel, healthcare, quantum computing, and other industries. It is covered by a small pool of analysts. Three verifiable, current price targets were reviewed: Canaccord Genuity at $11 (maintained September 16, 2026), Cantor Fitzgerald at $13 (initiated December 4, 2025 and reaffirmed in January 2026), and Lucid Capital at $15 (initiated October 27, 2025).
The simple average of these three targets is $13, matching the rounded central target used in the headline. The range is relatively narrow in percentage terms for such a volatile stock — $11 to $15 — but all three targets sit far above the current share price. Notably, these figures were largely set before, or early in, the stock's sharp 2026 selloff, and data providers have flagged that price targets "may not have had time to catch up" with the decline. The view is uniformly bullish (Strong Buy), but with only three analysts the sample is thin and should be treated with caution. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The shares closed near $1.23 in mid-November 2026, down more than 80% from their 52-week high above $8 and not far from their 52-week low. Reaching $13 would therefore require a gain of roughly 950%, an extraordinarily large move by any standard. There is no near-term, step-by-step path visible in current fundamentals; any move of this magnitude would require a fundamental re-rating driven by sustained commercialization, not a single catalyst.
The company is pre-profit: trailing-twelve-month revenue of about $31 million contrasts with a net loss exceeding $100 million and negative EPS (earnings per share) around -$1.50. Investors should understand that the $13 target represents a long-run, execution-dependent outcome rather than a reflection of today's income statement.
ASP Isotopes owns proprietary enrichment processes — the Aerodynamic Separation Process (ASP) and Quantum Enrichment (QE) — aimed at structurally short, high-value isotope markets. Recent developments include stable liquid-helium production at the Renergen Virginia Gas Project in South Africa (announced October 2026) and a heads-of-agreement framework for a South African high-assay low-enriched uranium (HALEU) joint venture. The company also holds cash (roughly $200 million) to fund scaling, and management has outlined an ambition of $300 million to $700 million in EBITDA by 2031. Continued helium ramp-up, nuclear-fuel demand, radiopharmaceutical acquisitions, and successful execution on isotope shipment volumes could all support a higher valuation. From what I see, the technology edge remains a key differentiator worth monitoring.
The principal obstacle is the gap between ambition and current financial reality. Heavy research and development spending and operating losses continue, and the share count has risen sharply (over 60% year over year), diluting existing holders. The company missed consensus EPS in its most recent reported quarter, and its beta of roughly 3.8 signals volatility far above the broader market. Targets set when the stock traded higher may overstate achievable upside if commercialization timelines slip, if helium and HALEU revenue scale more slowly than expected, or if dilution and cash burn persist. A move back toward $13 would also require clearing a very wide psychological and valuation gap.
The stock trades near its 52-week low, with its 50-day moving average around $2.41 — itself well below the analyst targets. The $1.00 level is a key psychological support, while prior trading ranges near $2.50–$4.00 represent potential resistance zones on any recovery. Long-term trend structure remains firmly downward, meaning any meaningful advance would first need to establish a base and reclaim these lower levels before the $13 objective becomes even remotely relevant. I’m watching this closely for any signs of stabilization.
Analyst price targets typically reflect a roughly 12-month research horizon, though firms do not always disclose an exact timeframe. For ASP Isotopes, the $13 figure should be read as a medium- to long-term aspiration tied to execution rather than a near-term forecast. Investors should monitor quarterly results and guidance, helium production and sales volumes, progress on the HALEU joint venture, radiopharmaceutical deals, analyst revisions and target changes, share issuance, and cash position. Any update to the company's 2031 EBITDA roadmap would also be directly relevant to the $13 objective.
Can ASP Isotopes reach $13? The $13 figure is the arithmetic mean of three verified analyst targets ranging from $11 to $15 — a uniform Strong Buy view, but one built on a small sample and set partly before the stock's collapse. From roughly $1.23, the required gain is about 950%, an extremely large move that would demand a complete transformation in execution: profitable helium and isotope commercialization, nuclear-fuel scale-up, and disciplined control of dilution and losses. The technology story and long-term EBITDA ambition are real, but the gap to profitability is equally real. The $13 target should be understood as a bullish, long-horizon aspiration rather than a near-term expectation, and it carries no guarantee.
For traders seeking a data-driven edge, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. The tool is designed to help investors discover new opportunities, keep tabs on existing positions, and spot changing trends more efficiently than manual screening. I rely on this resource regularly to cross-check ideas like the one discussed here and to stay on top of broader market shifts without spending hours on manual reviews. Explore the AI Daily Buy/Sell Signals to see how it can support your research process.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ASPI saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 66 similar instances where the indicator turned negative. In 59 of the 66 cases, the stock moved further down in the following days. The odds of a decline are at 89%.
The Moving Average Convergence Divergence Histogram (MACD) for ASPI turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 31 similar instances when the indicator turned negative. In 27 of the 31 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ASPI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for ASPI entered a downward trend on November 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +24.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where ASPI advanced for three days, in 198 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
ASPI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.202) is normal, around the industry mean (2.284). P/E Ratio (-1.634) is within average values for comparable stocks, (-17.137). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.548). Dividend Yield (0.000) settles around the average of (0.039) among similar stocks. P/S Ratio (11.062) is also within normal values, averaging (48.960).
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. ASPI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ASPI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry ChemicalsSpecialty